Gastric Cancer最新文献

{"title":"Phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases (WJOG10517G), including an individual patient data comparison with JCOG1108/WJOG7312G.","authors":"Toshiki Masuishi, Hiroki Hara, Takayuki Ando, Takeshi Kawakami, Yoshiyuki Yamamoto, Naotoshi Sugimoto, Kazuhiro Shiraishi, Taito Esaki, Yuji Negoro, Takao Tsuzuki, Hiroaki Sawai, Masato Nakamura, Takashi Inagaki, Yudai Shinohara, Kentaro Kawakami, Seiichiro Mitani, Kenji Tsuchihashi, Chihiro Kondoh, Hiroo Katsuya, Osamu Maeda, Yuriko Fujita, Kenichi Yoshimura, Masanori Terashima, Takako Eguchi Nakajima, Kei Muro","doi":"10.1007/s10120-026-01790-3","DOIUrl":"https://doi.org/10.1007/s10120-026-01790-3","url":null,"abstract":"<p><strong>Background: </strong>Advanced gastric cancer patients with severe peritoneal metastases, defined as massive ascites throughout the abdominal cavity and/or inadequate oral intake requiring intravenous infusion support, have been excluded from pivotal clinical trials.</p><p><strong>Methods: </strong>This phase II trial evaluated mFOLFOX6 in HER2-negative, chemotherapy-naive advanced gastric cancer patients with severe peritoneal metastases. The primary endpoint was overall survival (OS); secondary endpoints included ascites response rate among patients with massive ascites and oral intake improvement rate. A sample size of 50 was planned to detect a median OS of 9 months, with a threshold of 6 months (one-sided α = 0.05; β = 0.2). A prespecified individual patient data comparative analysis was performed using data from patients treated with 5-fluorouracil/l-leucovorin (FL) or FL plus paclitaxel (FLTAX) in JCOG1108/WJOG7312G.</p><p><strong>Results: </strong>Among 51 patients, Eastern Cooperative Oncology Group performance status was 0/1/2 in 3/40/8 patients. Median OS and progression-free survival were 7.4 (lower limit of one-sided 95% confidence interval [CI], 6.5) and 3.8 months, respectively. Among 25 patients with massive ascites, the ascites response rate was 36%. Of 33 patients with inadequate oral intake, 46% achieved improved oral intake. The most frequent grade 3-4 adverse event was neutropenia (51%), and febrile neutropenia occurred in one patient (2%). No treatment-related deaths occurred. In propensity score-weighted analysis, OS hazard ratios with mFOLFOX6 versus FL and FLTAX were 0.76 (95% CI 0.56-1.03) and 0.87 (95% CI 0.64-1.18), respectively.</p><p><strong>Conclusions: </strong>mFOLFOX6 was tolerable and may be a treatment option for advanced gastric cancer patients with severe peritoneal metastases.</p><p><strong>Clinical trial registration: </strong>jRCTs041180007.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis-predicting factor of gastrectomy after systemic cancer therapy for cStage IVB gastric cancer.","authors":"Takumi Habu, Takahiro Kinoshita, Daiki Terajima, Izuma Nakayama, Masahiro Yura, Mitsumasa Yoshida, Naoya Sakamoto, Takeshi Kuwata, Kohei Shitara","doi":"10.1007/s10120-026-01795-y","DOIUrl":"https://doi.org/10.1007/s10120-026-01795-y","url":null,"abstract":"<p><strong>Background: </strong>The clinical role of gastrectomy after systemic cancer therapy for cStage IVB gastric cancer (GC) remains controversial. This single-center study evaluated the clinical outcomes of gastrectomy after systemic cancer therapy in cStage IVB GC to identify prognosis-predicting factors.</p><p><strong>Methods: </strong>We retrospectively reviewed patients with cStage IVB GC who received systemic cancer therapy as initial treatment from 2013 to 2023 and subsequently underwent gastrectomy. Patients were categorized as having oligometastatic disease or polymetastatic disease based on pre-treatment disease status. Survival outcomes and prognostic factors were analyzed.</p><p><strong>Results: </strong>Among 1,591 patients who received systemic cancer therapy, 121 (7.6%) underwent gastrectomy (79 oligometastatic disease and 42 polymetastatic disease). The 3-year overall survival (OS) rate was 65% for the entire cohort. Patients with oligometastatic disease had better survival than those with polymetastatic disease (3-year OS: 76% vs. 43%, p = 0.009). Major pathological response (MPR) was observed in 39 patients (32%) and was associated with favorable survival in both oligometastatic (3-year OS: 97%) and polymetastatic disease (3-year OS: 89%). Further stratification showed similarly favorable survival in patients with clinical complete response and those without clinical complete response but with MPR, whereas patients without either response had poor outcomes (3-year OS: 94%, 95%, and 50%, respectively; p < 0.001).</p><p><strong>Conclusions: </strong>Postoperative prognosis after gastrectomy for cStage IVB GC appears to depend largely on pretreatment metastatic status and extent of response to systemic therapy. Technical resectability alone may be insufficient for surgical decision-making, particularly in polymetastatic disease.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148827486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Hepatic origin of increased serum TFF3 in gastric cancer bearing subjects.","authors":"Komei Kuge, Junko Mukohyama, Yoshimi Yasukawa, Yuko Ishibashi, Hiroki Masuda, Tomohiko Yasuda, Yasukazu Ohmoto, Hideyuki Takeshima, Akihisa Matsuda, Hiroshi Yoshida, Yasuyuki Seto, James R Goldenring, Toshikazu Ushijima, Sachiyo Nomura","doi":"10.1007/s10120-026-01794-z","DOIUrl":"10.1007/s10120-026-01794-z","url":null,"abstract":"","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148818242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mesenchymal R-spondin 3 promotes an immunogenic tumor microenvironment with adaptive immune resistance in human gastric adenocarcinoma.","authors":"Anne-Sophie Fischer, Alexander Arnold, Hilmar Berger, Stefanie Müllerke, Jonas Wizenty, Hans-Joachim Mollenkopf, David Horst, Frank Tacke, Christoph Treese, Michael Sigal","doi":"10.1007/s10120-026-01791-2","DOIUrl":"https://doi.org/10.1007/s10120-026-01791-2","url":null,"abstract":"<p><strong>Background: </strong>The main risk factor for gastric cancer (GC) is inflammation driven by Helicobacter pylori (H. pylori) infection. Despite growing use of immunotherapies targeting the tumor inflammatory microenvironment, responses remain suboptimal, highlighting the need to define inflammatory drivers and improve patient stratification.</p><p><strong>Methods: </strong>We assessed the role of R-spondin 3 (RSPO3), a stroma-secreted Wnt potentiator, in a Caucasian tissue microarray of 277 chemotherapy-naïve GC patients by associating RSPO3 expression with tumor inflammation, tumor stage, and survival. To mechanistically explore the role of Rspo3 in immune cell infiltration, we used conditional mouse models with stromal Rspo3 overexpression or knockout and infected them with H. pylori. We conditionally depleted the epithelial Rspo3 receptors Lgr4 and Lgr5 in mice to assess the mode of Rspo3 signaling. Findings were validated by generating a single-cell atlas from The Cancer Genome Atlas and performing gastric cancer transcriptome analysis.</p><p><strong>Results: </strong>Tumor RSPO3 expression positively associated with mucosal T-cell infiltration and combined positive score, a phenotype specific to intestinal-type GC. In mice, stromal Rspo3 promoted T-cell infiltration with increased interferon-γ signaling and PD-L1 expression in H. pylori-driven precancerous lesions. Epithelial depletion of Lgr4/5 reduced gastric T-cell infiltration and PD-L1 expression.</p><p><strong>Conclusions: </strong>In mice, mesenchymal-epithelial RSPO3-LGR4/5 signaling drives inflammation and enhances immune checkpoint signaling in precancerous lesions. Positive associations between RSPO3 expression and inflammation suggest that RSPO3 signaling contributes to shaping the immune microenvironment of human intestinal-type GC.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148812883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary outcomes of a phase II trial of laparoscopic/robotic total gastrectomy with spleen-preserving splenic hilar dissection for locally advanced proximal gastric cancer involving the greater curvature (JCOG1809).","authors":"Takahiro Kinoshita, Masayuki Yokoyama, Junya Kitadani, Takeshi Omori, Souya Nunobe, Shinji Kuroda, Michitaka Honda, Haruhiko Cho, Masaki Aizawa, Yukinori Kurokawa, Tomoya Tsukada, Shusuke Haruta, Kazunari Misawa, Kazuhisa Ehara, Kota Kawabata, Masanori Terashima, Takaki Yoshikawa","doi":"10.1007/s10120-026-01792-1","DOIUrl":"https://doi.org/10.1007/s10120-026-01792-1","url":null,"abstract":"<p><strong>Background: </strong>Advanced proximal gastric cancer (APGC) involving the greater curvature (Gre) sometimes metastasized to the splenic hilar lymph node (No.10 LN), so total gastrectomy with splenectomy has been the standard treatment aiming for complete removal of it; however, the high incidence of complications has been problematic.</p><p><strong>Methods: </strong>We conducted a multicenter phase-II trial to assess the safety and efficacy of laparoscopic or robotic spleen preserving splenic hilar dissection (LR-SHD) which has the potential to reduce complications. Eligibility criteria included cT2-4a resectable APGC involving the Gre without obvious No.10 metastasis. Macroscopic type 4 and large type 3 (≥ 8 cm) were excluded. LR-SHD with total gastrectomy (D2+No.10) was performed by qualified surgeons. The primary endpoint was the proportion of postoperative pancreatic fistula and/or intra-abdominal abscess (Grade ≥ III). The sample size was 85 considering a threshold of 16% and one-sided alpha of 0.1.</p><p><strong>Results: </strong>Between August 2019 and December 2024, 85 eligible patients (cT2/T3/T4a = 32/38/15) were enrolled, and resection was performed in 81. The median operation time was 379 min, and the median blood loss was 30 ml. No.10 metastasis was observed in 12.5% (10/80). Overall complications (Grade ≥ III) occurred in 9.9% (8/81). Pancreatic fistula and/or intra-abdominal abscess occurred in 1.2% (1/81; 80% confidence interval: 0.1-4.7%), which was significantly lower than prespecified threshold (one-sided p < 0.0001). No treatment-related mortality occurred.</p><p><strong>Conclusions: </strong>This study confirmed the safety and feasibility of LR-SHD when performed by experienced surgeons. This procedure is highly promising for treating APGC with the Gre invasion.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148812961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Identification of patients at risk for poor survival among those with normal skeletal muscle mass: a multicenter retrospective validation study in gastric cancer.","authors":"Ryota Matsui, Kazuyoshi Yamamoto, Yoshiro Yukawa, Masayoshi Terayama, Yukinori Kurokawa, Daisuke Ichikawa, Yoshitomo Yanagimoto, Takashi Oshima, Souya Nunobe, Takashi Kamei, Hiroya Takeuchi, Yoshihiro Nabeya, Masaki Kaibori, Naoki Hiki, Hidetoshi Eguchi, Yuichiro Doki","doi":"10.1007/s10120-026-01793-0","DOIUrl":"10.1007/s10120-026-01793-0","url":null,"abstract":"","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of surgical outcomes in laparoscopic gastrectomy for advanced gastric cancer between Japanese and Italian cohorts: an international, propensity score-matched investigation (the Shinkansen Study).","authors":"Pietro Maria Lombardi, Mitsumasa Yoshida, Gian Luca Baiocchi, Etsuro Bando, Alberto Biondi, Paolo De Martini, Stefano De Pascale, Federica Filippini, Gianluca Garulli, Simone Giacopuzzi, Federico Marchesi, Marco Milone, Sarah Molfino, Souya Nunobe, Massimo Oldani, Stefano Olmi, Stefano Rausei, Rossella Reddavid, Riccardo Rosati, Hisashi Shinohara, Kazumitsu Suzuki, Leonardo Solaini, Fabio Staderini, Jacopo Viganò, Davide Bernasconi, Giovanni Ferrari, Takahiro Kinoshita","doi":"10.1007/s10120-026-01788-x","DOIUrl":"https://doi.org/10.1007/s10120-026-01788-x","url":null,"abstract":"<p><strong>Background: </strong>Marked differences in advanced gastric cancer (AGC) surgical outcomes have historically been documented between Eastern and Western centers. This study compared laparoscopic gastrectomy (LG) surgical outcomes for AGC between Japanese and Italian institutions.</p><p><strong>Methods: </strong>This international, retrospective cohort study included patients undergoing LG for AGC at 17 Italian (within the Italian Research Group for Gastric Cancer) and 5 Japanese institutions (2015-2022). Propensity score matching (PSM) was used to balance baseline characteristics. The primary endpoint was 90-day severe morbidity (Clavien-Dindo ≥ III). Secondary endpoints were 90-day mortality, R0 resection rates, and lymph node (LN) yield. Multivariable regression identified predictors of severe morbidity.</p><p><strong>Results: </strong>From 1,617 patients, PSM selected 566 cases (283 per group). The Italian group (IG) showed a trend toward higher 90-day severe morbidity (14.8% vs. 9.2%, p = 0.052) and 90-day mortality (1.8% vs. 0.4%, p = 0.218) compared to the Japanese group (JG), though differences were not statistically significant. R0 resection rates were similar (96.1% vs. 98.6%, p = 0.115). Median harvested LNs were lower in the IG (34 vs. 43, p < 0.001). Multivariable analysis identified male sex and total gastrectomy, but not country of surgery, as independent predictors of 90-day severe morbidity.</p><p><strong>Conclusions: </strong>In propensity-matched cohorts, LG for AGC showed a clinical trend favoring the JG regarding severe morbidity, without reaching statistical significance. Country of surgery was not an independent predictor of severe complications. While some results are converging, suggesting an acceptable quality of care in Western institutions, the historical surgical gap between these specific Eastern and Western settings has not been completely bridged and better surgical outcomes in Japan persist.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148706375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic discordance and treatment-associated change of PD-L1 and CLDN18.2 in gastric cancer: a real-world analysis of paired biopsy-resection samples.","authors":"Donghe Yu, Tong Xie, Siyuan Cheng, Cheng Liu, Yifan Zhang, Bohan Zhang, Yingxuan Wang, Yang Feng, Yuxin Wang, Hongchao Gao, Erke Gao, Yan Wang, Chengxi Shi, Lin Shen, Zhi Peng","doi":"10.1007/s10120-026-01737-8","DOIUrl":"10.1007/s10120-026-01737-8","url":null,"abstract":"","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"737-749"},"PeriodicalIF":6.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exercise-nutrition prehabilitation attenuates lean body mass loss before gastrectomy: a randomized controlled trial.","authors":"Kazuyoshi Yamamoto, Naoki Shinno, Takeshi Omori, Yoshitomo Yanagimoto, Yasunori Masuike, Yuki Ushimaru, Kei Yamamoto, Keijiro Sugimura, Masaharu Shima, Masayuki Suzuki, Norihiro Matsuura, Takahito Sugase, Takeshi Kanemura, Yoshinori Kagawa, Kunihito Gotoh, Shogo Kobayashi, Hiroshi Miyata","doi":"10.1007/s10120-026-01747-6","DOIUrl":"10.1007/s10120-026-01747-6","url":null,"abstract":"<p><strong>Background: </strong>Older patients undergoing gastrectomy frequently exhibit sarcopenia and reduced physiologic reserve, increasing vulnerability to perioperative muscle loss. However, randomized evidence supporting multimodal exercise-nutrition prehabilitation in gastric cancer surgery remains limited. This trial evaluated whether prehabilitation attenuates preoperative lean body mass (LBM) loss and explored subgroups with greater benefit.</p><p><strong>Methods: </strong>In this single-center, open-label randomized controlled trial, patients aged ≥ 65 years with resectable gastric adenocarcinoma scheduled for curative gastrectomy were randomized 1:1 to standard care or multimodal prehabilitation. The intervention included daily walking, resistance training, and β-hydroxy-β-methylbutyrate supplementation. The primary endpoint was change in LBM from baseline to preoperative assessment. Secondary endpoints included physical function and postoperative outcomes. Prespecified subgroup and exploratory adherence analyses were conducted.</p><p><strong>Results: </strong>Of 110 randomized patients, 101 were analyzed (control, n = 52; prehabilitation, n = 49). Mean (SD) change in LBM was - 0.3 (1.2) kg in controls and 0.1 (1.0) kg with prehabilitation, yielding a mean difference of 0.4 kg (95% CI, 0.02-0.86; P = 0.043). Physical function and postoperative outcomes did not differ between groups. Greater LBM preservation was observed in women and in patients with lower baseline C-reactive protein or skeletal muscle index. Higher resistance training adherence was associated with greater LBM gain.</p><p><strong>Conclusions: </strong>Multimodal exercise-nutrition prehabilitation modestly preserved preoperative LBM in elderly gastrectomy patients but did not improve functional or postoperative outcomes. Risk-enriched trials are needed to determine whether targeted prehabilitation improves clinically meaningful endpoints.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"854-864"},"PeriodicalIF":6.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total versus subtotal gastrectomy following neoadjuvant flot chemotherapy for distal diffuse gastric adenocarcinoma: an international cohort study.","authors":"Jonathan Sivakumar, Darren J Wong, Katheryn Hall, Margaret M Lee, Cuong P Duong, David I Watson, Claire L Donohoe, Tim Bright, Ahmad Aly, Kevin Chan, David L Chan, Neil Merrett, Sivakumar Gananadha, Yick Ho Lam, Harsh Kanhere, BMark Smithers, Michael Bozin, Matthew Read, Krinal Mori, Mary-Ann Johnson, Enoch Wong, Sarah A Martin, Geraldine Ooi, Yahya Al-Habbal, Chon Hann Liew, Robert Bohmer, Jurstine Daruwalla, Mo Ballal, Rukshan Ranjan, Andrew D MacCormick, Sharon Pattison, Nicholas Evennett, Jason Robertson, James Tan, Alexandra Gordon, Simon Bann, Inian Samarasam, Ramesh Gurunathan, Jimmy So, Jonathan Yeung, Lorenzo Ferri, Ewen A Griffiths, Alexander W Phillips, Sheraz R Markar, David Chan, Thomas Murphy, John Reynolds, Magnus Nilsson, Guillaume Piessen, Bas Wijnhoven, Richard van Hillegersberg, Mark I van Berge Henegouwen, Pietro M Lombardi, David S Liu","doi":"10.1007/s10120-026-01746-7","DOIUrl":"10.1007/s10120-026-01746-7","url":null,"abstract":"","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"827-840"},"PeriodicalIF":6.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13314699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}